Innealta Capital LLC Sells 9,663 Shares of Elanco Animal Health Incorporated $ELAN

Innealta Capital LLC cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 49.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,016 shares of the company’s stock after selling 9,663 shares during the quarter. Innealta Capital LLC’s holdings in Elanco Animal Health were worth $143,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ELAN. HighTower Advisors LLC boosted its stake in Elanco Animal Health by 7.0% during the first quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock worth $131,000 after acquiring an additional 810 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Elanco Animal Health by 8.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock valued at $169,000 after purchasing an additional 944 shares during the last quarter. Graypoint LLC boosted its position in shares of Elanco Animal Health by 4.9% in the 1st quarter. Graypoint LLC now owns 26,845 shares of the company’s stock worth $282,000 after purchasing an additional 1,256 shares in the last quarter. Commerce Bank grew its stake in shares of Elanco Animal Health by 3.7% in the 1st quarter. Commerce Bank now owns 35,321 shares of the company’s stock worth $371,000 after buying an additional 1,256 shares during the last quarter. Finally, Probity Advisors Inc. boosted its holdings in Elanco Animal Health by 10.0% in the first quarter. Probity Advisors Inc. now owns 14,520 shares of the company’s stock worth $152,000 after acquiring an additional 1,314 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $21.48 on Friday. The stock has a market cap of $10.67 billion, a P/E ratio of 358.06, a P/E/G ratio of 3.30 and a beta of 1.71. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The stock’s fifty day moving average is $20.11 and its 200 day moving average is $16.07. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $22.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.51% and a net margin of 0.78%.The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the company posted $0.13 earnings per share. Elanco Animal Health’s revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ELAN. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price target for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Elanco Animal Health in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Piper Sandler lifted their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th. Finally, Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.